ArticleScientific reports2019
Proton-pump inhibitor use is associated with a broad spectrum of neurological adverse events including impaired hearing, vision, and memory.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 68 citations in OpenAlex.
- Proton pump inhibitors and risk of hearing loss; a systematic review.Naunyn-Schmiedeberg's archives of pharmacology · 2025Pooled it
- Association between proton pump inhibitor use and migraine: a systematic review and meta-analysis.The journal of headache and pain · 2025Pooled it
- Lansoprazole as a possible trigger of restless legs syndrome with suspected periodic limb movement disorder in a hemodialysis patient: a case report.CEN case reports · 2026Article
- A Phenome-Wide Comorbidity Atlas of Age-Related Hearing Loss, Speech-in-Noise Deficits, and Tinnitus: Distinguishing Causal Signals from Correlation.Journal of the Association for Research in Otolaryngology : JARO · 2025Article
- Gallic acid alleviates omeprazole-induced depressive behavior and memory impairment.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Effects of proton pump inhibitor (PPI) use on migraine - a critical review.The journal of headache and pain · 2025Review
- Neurological Manifestations Associated With Hypomagnesemia Due to Proton-Pump Inhibitors: A Case Series.Cureus · 2025Article
- Association betweenFrontiers in pharmacology · 2025Review
- Use of Acid-Suppression Therapy and Odds of Migraine and Severe Headache in the National Health and Nutrition Examination Survey.Neurology. Clinical practice · 2024Article
- Individualized prevention of proton pump inhibitor related adverse events by risk stratification.Nature communications · 2024Article
- Proton pump inhibitors and dementia: A nationwide population-based study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Diabetes mellitus and hearing loss.Molecular medicine (Cambridge, Mass.) · 2023Review
- Article
- Evaluating safety risks of whole-body cryotherapy/cryostimulation (WBC): a scoping review from an international consortium.European journal of medical research · 2023Article
- Proton Pump Inhibitor Use and Cognitive Function in the Boston Puerto Rican Health Study.The journals of gerontology. Series A, Biological sciences and medical sciences · 2023Article
- Effects of Proton Pump Inhibitors on Patient Survival in Patients Undergoing Maintenance Hemodialysis.Journal of clinical medicine · 2023Article
- Proton pump inhibitors display anti-tumour potential in glioma.Cell proliferation · 2023Review
- Chronic Tubulointerstitial Nephritis and Peripheral Neuropathy Probably Due to Pantoprazole Mimicking Systemic Disease.Hospital pharmacy · 2023Article
- Hippocampal synaptic dysfunction and spatial memory impairment in omeprazole-treated rats.Metabolic brain disease · 2022Article
- Characteristics and Patterns of Proton Pump Inhibitors Prescribing at the Primary Health Care.Medicina (Kaunas, Lithuania) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Proton-pump inhibitors, PPIs, are considered effective therapy for stomach acid suppression due to their irreversible inhibition of the hydrogen/potassium pump in the gastric parietal cells. They are widely prescribed and are considered safe for over-the-counter use. Recent studies have shown an association between PPI use and Alzheimer dementia, while others have disputed that connection. We analyzed over ten million United States Food and Drug Administration Adverse Event Reporting System reports, including over forty thousand reports containing PPIs, and provided evidence of increased propensity for memory impairment among PPI reports when compared to histamine-2 receptor antagonist control group. Furthermore, we found significant associations of PPI use with a wide range of neurological adverse reactions including, migraine, several peripheral neuropathies, and visual and auditory neurosensory abnormalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.